Advocates have also correctly noted that there isnt a single other medicine where Medicare considers the cost of a drug relative to its potential savings in determining coverage but maybe Medicare should start doing so
OLeary EM, Tian Y, Nigdelioglu R, Witt LJ, Cetin-Atalay R, Meliton AY, et al
Considering the antioxidant potencies of phenolic compounds and more generally of secondary metabolites, the connection of GSTs with secondary metabolism may be interesting from a pharmacological perspective
Over time, GeneDx plans to expand into newborn screening, a potentially $10 billion marketthen eventually into adult screening to replace multi-gene panel and individual gene tests, a future market pegged at $16 billion, Katherine Stueland, GeneDxs president and CEO, told GEN Edge last month With tougher comps in 25 and a potential headwind to revenues emerging in HCT, it is harder to argue for multiple expansion from here, Peterson said